A comparative study on the efficacy of coenzyme Q10 and amitriptyline in the prophylactic treatment of migraine headaches in childre

Phase 3

Conditions: Migraine headaches.
Migraine

Registration Number: IRCT20190208042654N2

Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 72

Inclusion Criteria

Children with migraine with or without aura referred to a clinic of neurology and disease is diagnosed definitively on the basis of IHS.
Migraine attacks occur at least twice a week or four times a month, forcing them to consume or disrupt their daily activities.
Children 5 to 15 year old

Exclusion Criteria

Patients' unwillingness to cooperate during the study.
Severe and uncontrolled side effects of Q10 or Amitriptyline
If a diagnosis other than migraine is made during the study, based on possible laboratory or imaging findings
Complicated migraine or epilepsy
Lack of ability to record data on the frequency, duration, and severity of headaches
Taking prophylaxis other than Q10 and amitriptyline
Children with migraines with severe psychiatric problems such as ADHD and depression
Using painkillers more than 4 times a week to control migraine attacks (severe forms of migraines)
A history of allergy to similar drugs

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of the effect of Q10 and amitriptyline on the prophylaxis of migraine headaches. Timepoint: Before intervention, 1,2 and 3 months after intervention. Method of measurement: PedMIDAS quality of life checklist.

Secondary Outcome Measures